Log in

2171 CARsgen Therapeutics Holdings Ltd. HKEX · China

CARsgen Therapeutics Holdings (2171) news

CARsgen Therapeutics Holdings Ltd. is a public biotech or pharmaceutical company listed on HKEX under the ticker 2171, recorded under China. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

Latest CARsgen Therapeutics Holdings news

We have not published a story on CARsgen Therapeutics Holdings yet. When there is news, it will appear here.

Questions about CARsgen Therapeutics Holdings

What is the ticker symbol of CARsgen Therapeutics Holdings?

CARsgen Therapeutics Holdings Ltd. trades under the ticker 2171 on HKEX.

Where is CARsgen Therapeutics Holdings listed?

CARsgen Therapeutics Holdings Ltd. is listed on HKEX.

Which country or territory is CARsgen Therapeutics Holdings listed under?

Our directory records CARsgen Therapeutics Holdings Ltd. under China.

What does CARsgen Therapeutics Holdings do?

Our directory classifies CARsgen Therapeutics Holdings Ltd. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.

What is the ISIN of CARsgen Therapeutics Holdings?

The ISIN recorded for CARsgen Therapeutics Holdings Ltd. is KYG1996C1006.

Does aibio.space cover CARsgen Therapeutics Holdings?

aibio.space lists CARsgen Therapeutics Holdings Ltd. among 2,820 public biotech companies and publishes its news here as stories appear.

Which companies are similar to CARsgen Therapeutics Holdings?

Companies in our directory listed in the same country and business area as CARsgen Therapeutics Holdings: Jinhe Biotechnology Co., Yifan Pharmaceutical Co., Hunan Er-Kang Pharmaceutical Co., Aurisco Pharmaceutical Co., CStone Pharmaceuticals, Zhejiang Tianyu Pharmaceutical Co..

Investor discussion: CARsgen Therapeutics Holdings

Members talk about CARsgen Therapeutics Holdings (2171). Reader posts, not aibio.space reporting, and not investment advice.

Rules
  1. Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
  2. Say whether you hold the stock. Every post states long, short or no position.
  3. No paid or sponsored posts. Do not post for anyone who pays or rewards you.
  4. No buy or sell calls and no price targets.
  5. No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
  6. No personal details and no spam. No links at all for your first 7 days as a member.

Posts that break the rules may be deleted without notice, and the account restricted or closed. See the terms and the privacy policy.

Capital-markets timeline

Financings, listing notices, splits, legal actions and other investor events at CARsgen Therapeutics Holdings, newest first. Each line links the filing it comes from.

  1. Financings

    Share or debt issue: COMPLETION OF PLACING OF EXISTING SHARES AND TOP-UP SUBSCRIPTION OF NEW SHARES UNDER GENERAL MANDATE. Source

  2. Financings

    Share or debt issue: CLARIFICATION ANNOUNCEMENT. Source

  3. Financings

    Share or debt issue: PLACING OF EXISTING SHARES AND TOP-UP SUBSCRIPTION OF NEW SHARES UNDER GENERAL MANDATE. Source

  4. Mergers

    Transaction under the Listing Rules: DISCLOSABLE TRANSACTION - ENTERING INTO THE STRATEGIC COOPERATION AGREEMENTS. Source

Press releases

Headlines of CARsgen Therapeutics Holdings's own announcements, newest first. Each opens the full release on the newswire that carried it.

  1. HKEXnews

    VOLUNTARY ANNOUNCEMENT - RESEARCH RESULTS OF SATRI-CEL AT THE ESMO CONGRESS 2026

  2. HKEXnews

    VOLUNTARY ANNOUNCEMENT - FIRST PATIENT DOSE OF CT0596 IN CHINA PHASE I REGISTRATIONAL TRIAL

  3. HKEXnews

    RESIGNATION OF NON-EXECUTIVE DIRECTOR AND NON-COMPLIANCE WITH RULE 3.21 OF THE LISTING RULES

  4. HKEXnews

    VOLUNTARY ANNOUNCEMENT - FIRST PATIENT DOSE OF CT1190B IN CHINA PHASE I REGISTRATIONAL TRIAL

  5. HKEXnews

    ANNOUNCEMENT OF INTERIM RESULTS FOR THE SIX MONTHS ENDED JUNE 30, 2026

  6. HKEXnews

    VOLUNTARY ANNOUNCEMENT - CT1190B RECEIVED IND CLEARANCE FROM THE NMPA FOR PATIENTS WITH RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA (R/R LBCL) WHO HAVE FAILED AT LEAST TWO PRIOR LINES OF STANDARD THERAPY

  7. HKEXnews

    VOLUNTARY ANNOUNCEMENT - CT0596 RECEIVED IND CLEARANCE FROM THE NMPA FOR THE TREATMENT OF PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (R/R MM)

  8. HKEXnews

    VOLUNTARY ANNOUNCEMENT - ABSTRACT OF RESEARCH RESULTS ON SATRI-CEL ACCEPTED FOR POSTER PRESENTATION AT ESMO CONGRESS 2026

  9. HKEXnews

    VOLUNTARY ANNOUNCEMENT - SHARE REPURCHASE BY THE COMPANY

  10. HKEXnews

    INSIDE INFORMATION ANNOUNCEMENT - THE NMPA APPROVES THE NEW DRUG APPLICATION FOR THE CLAUDIN18.2 CAR T-CELL THERAPY PRODUCT SATRICABTAGENE AUTOLEUCEL FOR THE TREATMENT OF PATIENTS WITH CLAUDIN18.2-POSITIVE, HER2-NEGATIVE ADVANCED GASTRIC/GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA (G/GEJA) WHO HAVE FAILED AT LEAST TWO PRIOR LINES OF THERAPY

  11. HKEXnews

    VOLUNTARY ANNOUNCEMENT - UPDATED RESEARCH RESULTS ON CT0596 AND CT1190B AT 2026 EHA ANNUAL CONGRESS

  12. HKEXnews

    VOLUNTARY ANNOUNCEMENT - UPDATED RESEARCH RESULTS ON SATRI-CEL AT THE 2026 ASCO ANNUAL MEETING

  13. HKEXnews

    COMPLETION OF PLACING OF EXISTING SHARES AND TOP-UP SUBSCRIPTION OF NEW SHARES UNDER GENERAL MANDATE

  14. HKEXnews

    NINTH AMENDED AND RESTATED MEMORANDUM AND ARTICLES OF ASSOCIATION

  15. HKEXnews

    POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON 22 MAY 2026

  16. HKEXnews

    CLARIFICATION ANNOUNCEMENT

  17. HKEXnews

    PLACING OF EXISTING SHARES AND TOP-UP SUBSCRIPTION OF NEW SHARES UNDER GENERAL MANDATE

  18. HKEXnews

    VOLUNTARY ANNOUNCEMENT - ABSTRACT OF RESEARCH RESULTS ON CT0596 AND CT1190B ACCEPTED FOR POSTER PRESENTATION AT 2026 EHA ANNUAL CONGRESS

  19. HKEXnews

    Letter to Registered Shareholders - Reminder letter regarding the Arrangement of Electronic Dissemination of Corporate Communications

  20. HKEXnews

    Letter to Non-registered Shareholders - Reminder letter regarding the Arrangement of Electronic Dissemination of Corporate Communications

Stock chart

Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. Open HKEX:2171 on TradingView.

Listing details

CARsgen Therapeutics Holdings Ltd. is a public biotech or pharmaceutical company listed on HKEX under the ticker 2171, recorded under China. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

Company
CARsgen Therapeutics Holdings Ltd.
Ticker
2171
Listing
HKEX
Country or territory
China
Business scope
Pharmaceuticals: Major
ISIN
KYG1996C1006
Last quote in directory
2026-10-22
Directory source
Listing page

Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. Tell us about a change. Work at this company? Claim this page.

Published and maintained by aibio.space. Not investment advice. How we work.

Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction

aibio.space

Full desks

Every other company has a starter desk. Search above to open one.

Settings

Appearance
Text size
Motion

Stops the news strip and the share rollers.

Your choices are saved in this browser only.

Free membership

Read aibio.space in full, free

Subscribe with your email address to read every story, company desk and profile in full. It costs nothing. In return, you agree that we may email you, including offers. One click to unsubscribe.

No card, no password. With email, we send one message to confirm your address first. With Google or Facebook we receive only your email address. Not investment advice.